admin
The federal government has just moved hard on a tiny part of kratom. The Drug Enforcement Administration filed Notices of Intent to temporarily place 7‑hydroxymitragynine (7‑OH) and three related synthetic derivatives into Schedule I when they exceed strict potency limits. In plain English: regulators want to treat some concentrated kratom products like the most dangerous illegal drugs while promising they won’t touch ordinary kratom leaf. That promise is thin comfort when bureaucrats draw a bright line and expect the world to behave neatly around it.
What the DEA actually did — and what the rule would mean
The DEA published notices starting in early July starting a short public‑comment clock and laying out the mechanics for temporary scheduling. If the temporary order is issued after the 30‑day window, the covered substances would immediately move into Schedule I, with all the criminal and regulatory weight that brings. The notices set a threshold: anything with more than 0.050% 7‑OH by dry weight, or more than 1.00 mg per product, could be swept up. Temporary scheduling can last up to two years while longer, full scientific review proceeds. That timeline and those thresholds will matter to small vendors, labs, retailers, and users.
Why regulators say they acted
HHS and the FDA told the DEA their scientific review shows concentrated or chemically altered 7‑OH products act like strong opioid agonists and can cause respiratory depression and dependence. The agencies point to rising poison‑center reports and seizures of synthetic 7‑OH products. “Today’s action targets highly concentrated, synthetic 7‑OH products, which pose a growing threat to public safety and health,” said DEA Administrator Terrance Cole. HHS Secretary Robert F. Kennedy, Jr. backed the move as well. They say the goal is to hit enhanced, concentrated products — not ordinary whole‑leaf kratom.
Why this move worries conservatives and consumers
We should take real public‑health threats seriously. But dumping a compound into Schedule I is a blunt instrument. Schedule I status makes research harder, criminalizes supply chains, and can push users toward unregulated black‑market alternatives — the exact opposite of harm reduction. Testing to enforce a 0.050% threshold is not trivial. Labs, retailers, and even courts will get stuck in fights about certificates and sampling. Bureaucrats love bright lines until somebody asks them to measure what’s on a spice jar.
A better path: common‑sense rules, not sweeping bans
If officials are serious about saving lives, they should regulate concentrated products without wrecking an industry or blocking research. Reasonable steps include clear potency caps, accurate labeling, child‑resistant packaging, age checks, third‑party testing, and fast funding for clinical study on 7‑OH and kratom’s role in opioid withdrawal. Let the public comment process run, weigh the data, and craft narrow rules that protect people without pretending every herbal remedy is heroin. The agencies can act decisively without turning centuries‑old plant use into a federal crime scene — and that would be the smart, conservative way to protect both liberty and public health.
